Table 1.

Summary of Characteristics of B-CLLs Analyzed

Apoptosis proteins-150 N  High (%) Low (%)  
 Bcl-2  57  34 (60)  23 (40) 
 Bax  57  27 (47)  30 (53)  
 Mcl-1  55 24 (44)  31 (56)  
 Bak  51  27 (53)  24 (47) 
 BAG-1  51  7 (14)  44 (86)  
 Caspase-3  52 18 (35)  34 (65)  
 Bcl-X  29  0 (0)  29 (100) 
 BAD  39  0 (0)  39 (100)  
 Bcl2:Bax ratio  53  33 (62)  20 (38) 
13q14 LOH-151  Positive Negative 
 48  15 (31)  33 (69)  
In vitro chemoresistance-152  Sensitive Resistant 
 42  29 (69) 13 (31)  
In vivo chemoresponse-153   CR  PR   NR 
 41  7 (17)  19 (46) 15 (37)  
Rai stage   Rai 0  Rai I/II    Rai III/IV 
 43  1 (2)  22 (51)  20 (47) 
Apoptosis proteins-150 N  High (%) Low (%)  
 Bcl-2  57  34 (60)  23 (40) 
 Bax  57  27 (47)  30 (53)  
 Mcl-1  55 24 (44)  31 (56)  
 Bak  51  27 (53)  24 (47) 
 BAG-1  51  7 (14)  44 (86)  
 Caspase-3  52 18 (35)  34 (65)  
 Bcl-X  29  0 (0)  29 (100) 
 BAD  39  0 (0)  39 (100)  
 Bcl2:Bax ratio  53  33 (62)  20 (38) 
13q14 LOH-151  Positive Negative 
 48  15 (31)  33 (69)  
In vitro chemoresistance-152  Sensitive Resistant 
 42  29 (69) 13 (31)  
In vivo chemoresponse-153   CR  PR   NR 
 41  7 (17)  19 (46) 15 (37)  
Rai stage   Rai 0  Rai I/II    Rai III/IV 
 43  1 (2)  22 (51)  20 (47) 

Data for B-CLL samples and patients are summarized (N = number tested). For 13q14LOH, ex vivo chemosensitivity, spontaneous apoptosis, and Rai stage, the frequency of patients in each response category is indicated, as well as the percentage of patients who were positive for 13q14LOH, exhibited sensitivity to drugs in vitro, had high rates of spontaneous apoptosis, or who had low Rai stage.

F0-150

Densitometry scores were dichotomized into high- and low-expression groups based on direct comparisons with R11846 cells (“high” ≥1.0 vs “low” <1.0. For Bcl-2, two different cutoffs were employed.

F0-151

13q14 LOH based on nine microsatellite markers.33 

F0-152

In vitro resistance to fludarabine defined as IC50>10−5 mol/L.

F0-153

High spontaneous apoptosis defined as 20% or more.